Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday.
Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75.
Wise suggests that recent conversations with six Transcatheter aortic valve replacement (TAVR) physicians and a follow-up survey of thirty doctors support the view that TAVR growth could re-accelerate in 2025.
These physicians are already seeing an increase in post-EARLY TAVR referrals, the analyst notes. Additionally, the FDA is expected to expand the asymptomatic severe aortic stenosis (AS) TAVR label in mid-2025, though some physicians are already treating patients before the label change.
According to Wise, TAVR growth slowed after COVID, causing Edwards shares to remain range-bound. However, with a more realistic 5-7% TAVR growth forecast for 2025, along with the positive new data and the expected label expansion, the analyst sees TAVR growth picking up again.
Also Read: Roper Technologies Q4 Earnings Beat, Surpasses $2 Billion Cash Flow Milestone
The analyst also highlights that the sale of Edwards’ Critical Care business to Becton, Dickinson and Company in September 2024 could positively impact Edwards' valuation.
With Critical Care being the company’s lowest-growth business and a non-structural heart asset, Edwards, now focused solely on structural heart, could potentially trade at a higher-than-historical multiple.
At Edwards’ most recent annual December Analyst Day event, CFO Scott Ullem highlighted the company's increased focus on operating leverage, which Wise notes.
Following the “transition year” in 2025, Edwards expects operating margin expansion of 50-100 basis points annually starting in 2026.
The analyst sees this shift towards margin expansion and EPS growth as a positive development. As 2026 approaches, investors may pay more attention to Edwards’ margin expansion potential and EPS growth prospects, the analyst writes.
Price Action: EW shares are trading higher by 3.69% to $73.75 at last check Thursday.
Read Next:
Photo by Ground Picture on Shutterstock.
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | UBS | Upgrades | Neutral | Buy |
| Jan 2022 | Morgan Stanley | Maintains | Overweight | |
| Jan 2022 | Raymond James | Maintains | Outperform |
View More Analyst Ratings for EW
View the Latest Analyst Ratings
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
This article Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.